NRXP Stock Overview
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics based on N-methyl-D-aspartate platform for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
NRx Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.18 |
| 52 Week High | US$12.00 |
| 52 Week Low | US$2.21 |
| Beta | 1.03 |
| 1 Month Change | -18.83% |
| 3 Month Change | -2.34% |
| 1 Year Change | -34.17% |
| 3 Year Change | -98.70% |
| 5 Year Change | -95.97% |
| Change since IPO | -95.65% |
Recent News & Updates
Shareholder Returns
| NRXP | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -24.4% | -2.2% | -3.7% |
| 1Y | -34.2% | 11.6% | 20.5% |
Return vs Industry: NRXP underperformed the US Pharmaceuticals industry which returned 11.7% over the past year.
Return vs Market: NRXP underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| NRXP volatility | |
|---|---|
| NRXP Average Weekly Movement | 22.4% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NRXP's share price has been volatile over the past 3 months.
Volatility Over Time: NRXP's weekly volatility has increased from 16% to 22% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | Steve Willard | www.nrxpharma.com |
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics based on N-methyl-D-aspartate platform for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated investigational breakthrough therapy for suicidal treatment-resistant bipolar depression and chronic pain; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of acute suicidality in depression. The company has a partnership with Alvogen and Lotus to develop and commercialize NRX-101 for the suicidal bipolar depression treatment, as well as an agreement with Nephron Pharmaceuticals, Inc. to develop ketamine.
NRx Pharmaceuticals, Inc. Fundamentals Summary
| NRXP fundamental statistics | |
|---|---|
| Market cap | US$40.86m |
| Earnings (TTM) | -US$30.16m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.3x
P/E RatioIs NRXP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NRXP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$30.16m |
| Earnings | -US$30.16m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.17 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -78.1% |
How did NRXP perform over the long term?
See historical performance and comparison